PMID- 19210143
OWN - NLM
STAT- MEDLINE
DCOM- 20090414
LR  - 20190911
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 25
IP  - 1
DP  - 2009 Jan
TI  - Safety of sublingual immunotherapy started during the pollen season.
PG  - 103-7
LID - 10.1185/03007990802591673 [doi]
AB  - BACKGROUND: Sublingual immunotherapy (SLIT) is safer than subcutaneous 
      immunotherapy (SCIT) and this has lead to the reconsideration of the use of 
      ultra-rush schedules for SLIT. The aim of this study was to assess the safety of 
      ultra-rush SLIT in pollen-allergic children according to different timing of 
      administration in relation to the pollen season. METHODS: In total, 34 children 
      with pollen-induced rhinitis and 36 with pollen-induced asthma and rhinitis, were 
      enrolled and assigned to three study groups: group 1 (n = 17 patients): 
      conventional pre-seasonal-SLIT treatment; group 2 (n = 23 patients), seasonal 
      SLIT ended before the pollen seasonal peak; group 3 (n = 30 patients), SLIT began 
      after the pollen seasonal peak and ended after the pollen season. SLIT was 
      performed using extracts from Stallergenes (Antony, France) and following an 
      ultra-rush schedule, consisting in four doses at a 30-min intervals, and 
      maintenance treatment by administering the top dose three times a week. RESULTS: 
      In all, 54 adverse events (AEs) were reported: 12 in nine patients in group 1 
      (9/17, 52.9%), 22 in 14 patients in group 2 (14/23, 60.9%), and 20 in 13 patients 
      in group 3 (13/30, 43.3%). No statistically significant differences were found 
      between the three groups. Local AEs (oral itching and burning) were short lasting 
      and self-resolving. Systemic AEs were also mild, except for a case of asthma, 
      which lasted 5 days, in a patient from group 1. There were no severe reactions, 
      and none of the patients dropped out. CONCLUSIONS: This study suggests that SLIT 
      with pollen extracts may be safely started at the beginning and also during the 
      pollen season, with a tolerability profile comparable to the conventional 
      pre-seasonal SLIT.
FAU - Ariano, Renato
AU  - Ariano R
AD  - Allergy Department, ASL1 Imperiese, Bordighera, Italy.
FAU - Incorvaia, Cristoforo
AU  - Incorvaia C
FAU - La Grutta, Stefania
AU  - La Grutta S
FAU - Marcucci, Francesco
AU  - Marcucci F
FAU - Pajno, Giovanbattista
AU  - Pajno G
FAU - Sensi, Laura
AU  - Sensi L
FAU - Di Cara, Giuseppe
AU  - Di Cara G
FAU - Sieber, Jochen
AU  - Sieber J
FAU - Yacoub, Mona-Rita
AU  - Yacoub MR
FAU - Frati, Franco
AU  - Frati F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Allergens)
SB  - IM
MH  - Administration, Sublingual
MH  - Adolescent
MH  - Allergens/*administration & dosage
MH  - Asthma/*therapy
MH  - Child
MH  - Child, Preschool
MH  - Desensitization, Immunologic/*adverse effects
MH  - Humans
MH  - *Pollen
MH  - Rhinitis, Allergic, Seasonal/*therapy
EDAT- 2009/02/13 09:00
MHDA- 2009/04/15 09:00
CRDT- 2009/02/13 09:00
PHST- 2009/02/13 09:00 [entrez]
PHST- 2009/02/13 09:00 [pubmed]
PHST- 2009/04/15 09:00 [medline]
AID - 10.1185/03007990802591673 [pii]
AID - 10.1185/03007990802591673 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2009 Jan;25(1):103-7. doi: 10.1185/03007990802591673.